Morphological features of TMPRSS2-ERG gene fusion prostate cancer

Journal of Pathology

Volumn 212, Issue 1, 2007, Pages 91-101

  Mosquera, J M ^a,b   Perner, S ^a,b,c   Demichelis, F ^a,b,d   Kim, R ^a   Hofer, M D ^a,b   Mertz, K D ^a,b   Paris, P L ^e   Simko, J ^e   Collins, C ^e   Bismar, T A ^f   Chinnaiyan, A M ^g   Rubin, M A ^a,b,h,i  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ULM   (Germany)

^d ITC IRST   (Italy)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MCGILL UNIVERSITY   (Canada)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h BROAD INSTITUTE OF MIT AND HARVARD   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Bluetinged mucin; Collagenous micronodules; Cribriform growth pattern; Fluorescence in situ hybridization (FISH); Gene fusion; Intraductal tumour spread; Macronucleoli; Signet ring cell features; Translocation

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; GENE PRODUCT; HYBRID PROTEIN; MUCIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN TMPRSS2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER INVASION; CANCER RISK; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MORPHOLOGICAL TRAIT; OBSERVER VARIATION; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RISK ASSESSMENT; STATISTICAL ANALYSIS;

BIOPSY, NEEDLE; CA-15-3 ANTIGEN; DNA-BINDING PROTEINS; GENE FUSION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; MALE; MIDDLE AGED; MUCINS; NEOPLASM STAGING; PHENOTYPE; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 34248569769     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2154     Document Type: Article

References (63)

1. Alexander J, Watanabe T, Wu TT Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 2001;158:527-535.
2. Greenson JK, Bonner JD, Ben-Yzhak O, Cohen HI, Miselevich I, Resnick MB, et al. Phenotype of microsatellite unstable colorectal carcinomas: well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol 2003; 27:563-570.
3. Halvarsson B, Muller W, Planck M, Benoni AC, Mangell P, Ottosson J, et al. Phenotypic heterogeneity in hereditary non-polyposis colorectal cancer: identical germline mutations associated with variable tumor morphology and immunohistochemical expression. J Clin Pathol 2006;Aug 10 [Epub ahead of print].
4. Jass JR. Pathology of hereditary nonpolyposis colorectal cancer. Ann N Y Acad Sci 2000;910:62-73; discussion 73-74.
5. Lynch HT, Smyrk T, Lynch JF. Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch syndrome). Int J Cancer 1996;69:38-43.
6. Lakhani SR. The pathology of familial breast cancer: morphological aspects. Breast Cancer Res 1999;1:31-35.
7. Lakhani SR, Jacquernier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998;90:1138-1145.
8. Baisden BL, Kahane H, Epstein JI. Perineural invasion, mucinous fibroplasia, and glomerulations: diagnostic features of limited cancer on prostate needle biopsy. Am J Surg Pathol 1999; 23:918-924.
9. Epstein JI. Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum Pathol 1995;26:223-229.
10. Epstein JI. Diagnosis and reporting of limited adenocarcinoma of he prostate on needle biopsy. Mod Pathol 2004;17:307-315.
11. Thorson P, Vollmer RT, Arcangeli C, Keetch DW, Humphrey PA. Minimal carcinoma in prostate needle biopsy specimens: diagnostic features and radical prostatectomy follow-up. Mod Pathol 1998; 11:543-551.
12. Argani P, Antonescu CR, Illei PB, Lui MY, Timmons CF, Newbury R, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol 2001;159:179-192.
13. Argani P, Lae M, Ballard ET, Amin M, Manivel C, Hutchinson B, et al. Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol 2006;24:1529-1534.
14. Argani P, Lae M, Hutchinson B, Reuter VE, Collins MH, Perentesis J, et al. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by imnumohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol 2005;29:230-240.
15. Bruder E, Passera O, Harms D, Leuschner I, Ladanyi M, Argani P, et al. Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol 2004; 28:1117-1132.
16. Fulford LG, Easton DF, Reis-Filho JS, Softonis A, Gillett CE, Lakhani SR, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006;49:22-34.
17. Eble JN, Sauter G, Epstein JI, Sesterhann IAE. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Male Urinary System and Male Gential Organs. IARC Press: Lyon, 2004.
18. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006; 38:652-658.
19. Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, Waliszewska A, et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci USA 2006; 103:14068-14073.
20. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006;66:3396-3400.
21. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648.
22. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006; 66:8337-8341.
23. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (in press).
24. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
25. Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, Panagopoulos I. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 2006;45:717-719.
26. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006;66:8347-8351.
27. Yoshimoto M, Joshua AM, Chilton-Macneill S, Bayani J, Selvarajah S, Evans AJ, et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006;8:465-469.
28. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;Jan 22 [Epub ahead of print].
29. Bova GS, Parmigiani G, Epstein JI, Wheeler T, Mucci NR, Rubin MA. Web-based tissue microarray image data analysis: initial validation testing through prostate cancer Gleason grading. Hum Pathol 2001;32:417-427.
30. Rubin MA, de La Taille A, Bagiella E, Olsson CA, O'Toole KM. Cribriform carcinoma of the prostate and cribriform prostatic intraepithelial neoplasia: incidence and clinical implications. Am J Surg Pathol 1998;22:840-848.
31. Zhou M, Shah R, Shen R, Rubin MA. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells. Am J Surg Pathol 2003;27:365-371.
32. Rubin MA, Bismar TA, Andren O, Mucci L, Kim R, Shen R, et al. Decreased {alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 2005;14:1424-1432.
33. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
34. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874.
35. Iczkowski KA, Bostwick DG. Criteria for biopsy diagnosis of minimal volume prostatic adenocarcinoma: analytic comparison with nondiagnostic but suspicious atypical small acinar proliferation. Arch Pathol Lab Med 2000;124:98-107.
36. Arai T, Fujita K, Fujime M, Irimura T. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis. Int J Urol 2005;12:654-661.
37. Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, et al. Defining aggressive prostate cancer using a 12-gene model. Neoplasia 2006;8:59-68.
38. Saez C, Japon MA, Conde AF, Poveda MA, Luna-More S, Segura DI. Sialomucins are characteristically O-acylated in poorly differentiated and colloid prostatic adenocarcinomas. Mod Pathol 1998; 11:1193-1197.
39. Torbenson M, Dhir R, Nangia A, Becich MJ, Kapadia SB. Prostatic carcinoma with signet ring cells: a clinicopathologic and immunohistochemical analysis of 12 cases, with review of the literature. Mod Pathol 1998;11:552-559.
40. McNeal JE, Reese JH, Redwine EA, Freiha FS, Stamey TA. Cribriform adenocarcinoma of the prostate. Cancer 1986;58:1714-1719.
41. McNeal JE, Yemoto CE. Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. Am J Surg Pathol 1996;20:802-814.
42. Cohen RJ, McNeal JE, Baillie T. Patterns of differentiation and proliferation in intraductal carcinoma of the prostate: significance for cancer progression. Prostate 2000;43:11-19.
43. Guo CC, Epstein JI. Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance. Mod Pathol 2006;19:1528-1535.
44. Bostwick DG, Wollan P, Adlakha K. Collagenous micronodules in prostate cancer. A specific but infrequent diagnostic finding. Arch Pathol Lab Med 1995;119:444-447.
45. Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, Jeronimo C, et al. TMPRSS2-ERG gene fusion causing ERG over-expression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006;8:826-832.
46. Epstein JI, Fynheer J. Acidic mucin in the prostate: can it differentiate adenosis from adenocarcinoma? Hum Pathol 1992; 23:1321-1325.
47. Goldstein NS, Qian J, Bostwick DO. Mucin expression in atypical adenomatous hyperplasia of the prostate. Hum Pathol 1995; 26:887-891.
48. Ro JY, Grignon DJ, Troncoso P, Ayala AG. Mucin in prostatic adenocarcinoma. Semin Diagn Pathol 1988;5:273-283.
49. Helpap B. Differential diagnosis of glandular proliferations in the prostate. A conventional and immunohistochernical approach. Virchows Arch 1998;433:397-405.
50. Amin MB, Schultz DS, Zarbo RJ. Analysis of cribriform morphology in prostatic neoplasia using antibody to high-molecular-weight cytokeratins. Arch Pathol Lab Med 1994;118:260-264.
51. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29:1228-1242.
52. Wheeler TM, Dillioglugil O, Kattan MW, Arakawa A, Soh S, Suyama K, et al. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1 - 2 prostate cancer. Hum Pathol 1998;29:856-862.
53. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993; 71:3582-3593.
54. Bastacky SI, Walsh PC, Epstein JI. Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular penetration in clinical stage B adenocarcinoma of the prostate. Am J Surg Pathol 1993;17:336-341.
55. Ali TZ, Epstein JI. Perineural involvement by benign prostatic glands on needle biopsy. Am J Surg Pathol 2005;29:1159-1163.
56. Guerin D, Hasan N, Keen CE. Signet ring cell differentiation in adenocarcinoma of the prostate: a study of five cases. Histopathology 1993;22:367-371.
57. Bostwick DG, Eble JN. Urologic Surgical Pathology. Mosby: St Louis, MO, 1997.
58. Nelson RS, Epstein JI. Prostatic carcinoma with abundant xanthomatous cytoplasm. Foamy gland carcinoma. Am J Surg Pathol 1996; 20:419-426.
59. Tran TT, Sengupta E, Yang XJ. Prostatic foamy gland carcinoma with aggressive behavior: clinicopathologic, immunohistochemical, and ultrastructural analysis. Am J Surg Pathol 2001;25:618-623.
60. Bostwick DG, Kindrachuk RW, Rouse RV. Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings. Am J Surg Pathol 1985;9:595-609.
61. Epstein JI, Woodruff JM. Adenocarcinoma of the prostate with endometrioid features. A light microscopic and immunohistochemical study of ten cases. Cancer 1986;57:111-119.
62. Ro JY, Tetu B, Ayala AG, Orddnez NG. Small cell carcinoma of the prostate. II. Immunohistochemical and electron microscopic studies of 18 cases. Cancer 1987;59:977-982.
63. Tetu B, Ro TY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer 1987;59:1803-1809.